{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:06:35Z","timestamp":1758636395267,"version":"3.37.3"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","award":["21517"],"award-info":[{"award-number":["21517"]}],"id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018817","name":"LUPUS UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.rpth.2024.102468","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T14:40:18Z","timestamp":1717598418000},"page":"102468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-0988","authenticated-orcid":false,"given":"Prabal","family":"Mittal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-1270","authenticated-orcid":false,"given":"Rafael","family":"Gafoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-9257","authenticated-orcid":false,"given":"Zara","family":"Sayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-2845","authenticated-orcid":false,"given":"Maria","family":"Efthymiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0348-0639","authenticated-orcid":false,"given":"Ibrahim","family":"Tohidi-Esfahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Appiah-Cubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa J.","family":"Arachchillage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1124-6666","authenticated-orcid":false,"given":"David","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3772-7049","authenticated-orcid":false,"given":"Ekaterina","family":"Bordea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jorge","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Caverly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Chandratheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Gates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Rolf","family":"Ja\u00a8ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-2689","authenticated-orcid":false,"given":"Arvind","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bunis","family":"Packham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaye","family":"Paskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-8294","authenticated-orcid":false,"given":"Jignesh P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Round","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Werring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-390X","authenticated-orcid":false,"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102468_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jstrokecerebrovasdis.2004.06.003","article-title":"Is stroke most common cause of disability?","volume":"13","author":"Adamson","year":"2004","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"suppl 10","key":"10.1016\/j.rpth.2024.102468_bib3","article-title":"Systemic Lupus erythematosus: detailed anatomy of a cohort (follow-up for more than 35 years)","volume":"68","author":"Gracia-Tello","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rpth.2024.102468_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archinte.164.1.77","article-title":"High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus","volume":"164","author":"Ruiz-Irastorza","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rpth.2024.102468_bib5","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1177\/0961203320950477","article-title":"Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality","volume":"29","author":"Riancho-Zarrabeitia","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102468_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rpth.2024.102468_bib7","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review","volume":"74","author":"Sciascia","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2024.102468_bib8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in antiphospholipid syndrome during a 10 year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2024.102468_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3174\/ajnr.A3645","article-title":"Brain MR findings in patients with systemic lupus erythematosus with and without antiphospholipid antibody syndrome","volume":"35","author":"Kaichi","year":"2014","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.rpth.2024.102468_bib10","doi-asserted-by":"crossref","first-page":"c3666","DOI":"10.1136\/bmj.c3666","article-title":"The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis","volume":"341","author":"Debette","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102468_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/rheumatology\/keab452","article-title":"Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review","volume":"61","author":"Donnellan","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rpth.2024.102468_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000924","article-title":"Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing EULAR recommendations for management of antiphospholipid syndrome in adults","volume":"5","author":"Tektonidou","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.rpth.2024.102468_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rpth.2024.102468_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1055\/s-0038-1627100","article-title":"Population Impact of drug interactions with warfarin: a real-world data approach","volume":"118","author":"Mart\u00edn-P\u00e9rez","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102468_bib15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jth.15217","article-title":"Monitoring of anticoagulation in thrombotic antiphospholipid syndrome","volume":"19","author":"Cohen","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102468_bib16","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.rpth.2024.102468_bib17","article-title":"Xarelto (rivaroxaban) 15 mg and 20 mg film coated tablets","author":"Bayer","year":"2023","journal-title":"Summary of product characteristics"},{"key":"10.1016\/j.rpth.2024.102468_bib20","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force Report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.rpth.2024.102468_bib21","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102468_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102711","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"20","author":"Dufrost","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rpth.2024.102468_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2024.102468_bib25","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE (RAPS): a randomised controlled open label phase 2\/3 non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematology"},{"key":"10.1016\/j.rpth.2024.102468_bib26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102468_bib27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2024.102468_bib28","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102468_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/jcbfm.2015.113","article-title":"Progression of MRI markers in cerebral small vessel disease: Sample size considerations for clinical trials","volume":"36","author":"Benjamin","year":"2016","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.rpth.2024.102468_bib30","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"Van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102468_bib31","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","article-title":"Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism","volume":"131","author":"Kearon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102468_bib32","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/jth.14720","article-title":"Prevalence of confirmed anti- phospholipid syndrome in 18\u201350 years unselected patients with first unprovoked venous thromboembolism","volume":"18","author":"Miranda","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102468_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939- an oral, direct Factor Xa inhibitor- after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2024.102468_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2024.102468_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In\u00a0vitro and in\u00a0vivo studies of novel antithrombotic agent BAY 59-7939\u2014an oral, direct factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102468_bib36","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102468_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40256-020-00449-3","article-title":"Rivaroxaban versus warfarin in patients with mechanical heart valves: open-label, proof-of-concept trial\u2014RIWA study","volume":"21","author":"Duraes","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.rpth.2024.102468_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102468_bib39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamainternmed.2013.3037","article-title":"Surrogate outcomes in clinical trials: a cautionary tale","volume":"173","author":"Svensson","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.rpth.2024.102468_bib40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamaneurol.2022.2262","article-title":"Framework for clinical trials in cerebral small vessel disease (FINESSE): a review","volume":"79","author":"Markus","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.rpth.2024.102468_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/bbde462e-c699-4c4d-9b61-050c7e6e5ce3","article-title":"Mechanisms of cognitive impairment in cerebral small vessel disease: multimodal MRI results from the St George's cognition and neuroimaging in stroke (SCANS) study","volume":"8","author":"Lawrence","year":"2013","journal-title":"PLoS One"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T14:38:57Z","timestamp":1725028737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2475037924001572"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102468","relation":{},"ISSN":["2475-0379"],"issn-type":[{"type":"print","value":"2475-0379"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102468"}}